Title : Evaluation of the inhibitory effects of antigout drugs on human carboxylesterases in vitro - Liang_2024_Toxicol.In.Vitro_98_105833 |
Author(s) : Liang JH , Yi XL , Gong JM , Du Z |
Ref : Toxicol In Vitro , 98 :105833 , 2024 |
Abstract :
Gout is an immune-metabolic disease that frequently coexists with multiple comorbidities such as chronic kidney disease, cardiovascular disease and metabolic syndrome, therefore, it is often treated in combination with these complications. The present study aimed to evaluate the inhibitory effect of antigout drugs (allopurinol, febuxostat, topiroxostat, benzbromarone, lesinurad and probenecid) on the activity of the crucial phase I drug-metabolizing enzymes, carboxylesterases (CESs). 2-(2-benzoyl-3-methoxyphenyl) benzothiazole (BMBT) and fluorescein diacetate (FD) were utilized as the probe reactions to determine the activity of CES1 and CES2, respectively, through in vitro culturing with human liver microsomes. Benzbromarone and lesinurad exhibited strong inhibition towards CESs with Ki values of 2.16 and 5.15 microM for benzbromarone towards CES1 and CES2, respectively, and 2.94 microM for lesinurad towards CES2. In vitro-in vivo extrapolation (IVIVE) indicated that benzbromarone and lesinurad might disturb the metabolic hydrolysis of clinical drugs in vivo by inhibiting CESs. In silico docking showed that hydrogen bonds and hydrophobic interactions contributed to the intermolecular interactions of antigout drugs on CESs. Therefore, vigilant monitoring of potential drug-drug interactions (DDIs) is imperative when co-administering antigout drugs in clinical practice. |
PubMedSearch : Liang_2024_Toxicol.In.Vitro_98_105833 |
PubMedID: 38670244 |
Liang JH, Yi XL, Gong JM, Du Z (2024)
Evaluation of the inhibitory effects of antigout drugs on human carboxylesterases in vitro
Toxicol In Vitro
98 :105833
Liang JH, Yi XL, Gong JM, Du Z (2024)
Toxicol In Vitro
98 :105833